mometasone furoate nasal spray / Generic mfg. - LARVOL DELTA

Progressive vestibular dysfunction in unilateral acute otitis media with serous labyrinthitis: a case report. (PubMed, J Med Case Rep) - "Patients with vertigo and labyrinthitis secondary to acute otitis media typically exhibit variable vestibular symptoms, with unidirectional irritative nystagmus serving as a cardinal diagnostic sign. Integration of audiological and vestibular function assessments, including meticulous surveillance of clinical evolution, is paramount to prevent misdiagnosis or treatment delay. The differential impacts of toxic versus inflammatory mediators on inner ear physiology may render early combination therapy with antibiotics and glucocorticoids particularly efficacious."

Journal • Ophthalmology • Otorhinolaryngology • Vertigo

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

BiRCh: A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) (clinicaltrials.gov) - P2 | N=288 | Completed | Sponsor: Insmed Incorporated | Active, not recruiting ➔ Completed

Trial completion • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Efficacy Evaluation of Omalizumab Injection in Patients with Uncontrolled Perennial Moderate-to-Severe Allergic Rhinitis: A Multicenter, Randomized, Open-Label, Investigator-Initiated Study （OPERA Study） (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital

New P4 trial • Allergic Rhinitis • Immunology • Inflammation

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQC2731 Injection in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (ChiCTR) - P3 | N=200 | Not yet recruiting | Sponsor: Eye & ENT hospital of Fudan University; Eye & ENT hospital of Fudan University

New P3 trial • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

DUPILUMAB VS OMALIZUMAB: GREATER LUNG FUNCTION IMPROVEMENTS IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND UNCONTROLLED ASTHMA (EVEREST) WITH DUPILUMAB (CHEST 2025) - P4 | "Patients $18 years of age with severe CRSwNP and coexisting uncontrolled asthma received background mometasone furoate nasal spray and were randomized 1:1 to receive add-on dupilumab 300 mg every 2 weeks or omalizumab 75–600 mg every 2 or 4 weeks for 24 weeks. Dupilumab provides greater improvement than omalizumab for large and small airway lung function outcomes in patients with CRSwNP and uncontrolled coexisting asthma, which can be a surrogate for improved asthma control and reduced risk for exacerbations. CLINICAL IMPLICATIONS: These results may aid physicians in selecting appropriate biologic therapy for patients with CRSwNP and uncontrolled asthma."

Clinical • Late-breaking abstract • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

The impact of bacterial lysate (OM-85) on clinical and immunological parameters in children with allergic rhinitis. (PubMed, Eur Arch Otorhinolaryngol) - "OM-85 adjunctive therapy can enhance immune function, improve clinical symptoms, and enhance quality of life in children with allergic rhinitis."

Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. (PubMed, Lancet Respir Med) - P4 | "Dupilumab was superior to omalizumab in patients with severe CRSwNP and coexisting asthma. These findings support the efficacy of dupilumab in patients with type 2 respiratory diseases versus an active biologic comparator, the known safety profiles of dupilumab and omalizumab, and could enable better treatment targeting for patients with CRSwNP and asthma in clinical practice."

Head-to-Head • Journal • P4 data • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Cough • Immunology • Infectious Disease • Inflammation • Nasal Polyps • Otorhinolaryngology • Pain • Pulmonary Disease • Respiratory Diseases • Sinusitis • IL13

Clinical Efficacy of Spray-Type Nasal Allergen Blocker as Adjuvant Treatment for Pediatric Allergic Rhinitis. (PubMed, Ann Otol Rhinol Laryngol) - "Combination of Spray-Type Nasal Allergen Blocker and Mometasone Furoate Aqueous Nasal Spray exhibits promising results in the treatment of pediatric AR compared to Mometasone Furoate Aqueous Nasal Spray alone."

Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pediatrics • IFNG • TGFB1

Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps: The CROWNS-2 Randomized Clinical Trial. (PubMed, JAMA) - P3 | "Four weeks after initiation of mometasone furoate nasal spray, 100 µg in each nostril daily, patients were randomized to receive subcutaneous stapokibart, 300 mg, or placebo (1:1) every 2 weeks for 24 weeks...Among patients with severe chronic rhinosinusitis with nasal polyps treated with a daily intranasal corticosteroid, stapokibart reduced polyp size and severity of nasal symptoms at 24 weeks. ClinicalTrials.gov Identifier: NCT05436275."

Clinical • Journal • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Eosinophilia • Immunology • Musculoskeletal Pain • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis

Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Wuhan Union Hospital, China | Trial completion date: Dec 2025 ➔ May 2026 | Trial primary completion date: Sep 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Allergic Rhinitis • Immunology • Inflammation

VAT: Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (clinicaltrials.gov) - P=N/A | N=200 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New trial • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Efficacy and safety of dupilumab versus omalizumab in patients with severe chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): Results from a prospective, head-to-head phase 4 trial (EAACI 2025) - P4 | "Adults with severe CRSwNP and coexisting asthma were randomised 1:1 to dupilumab 300 mg every 2 weeks or omalizumab 75‒600 mg every 2 or 4 weeks for 24 weeks on background mometasone furoate nasal spray. Conclusion In EVEREST, dupilumab demonstrated superiority over omalizumab in patients with severe CRSwNP and coexisting asthma. This study supports the efficacy of dupilumab in type 2 respiratory diseases versus an active biologic comparator, and supports the known safety profiles of dupilumab and omalizumab."

Clinical • Head-to-Head • Late-breaking abstract • P4 data • Immunology

LT: Combination of Oral Supplement With Fatty Acids, Vitamin B6, Perilla, and Liquorice With Nasal Steroids for the Treatment of Allergic Rhinitis (clinicaltrials.gov) - P1 | N=400 | Completed | Sponsor: Isola Tiberina - Gemelli Isola Hospital, Rome, Italy

New P1 trial • Allergic Rhinitis • Immunology • Inflammation

Protocol for the clinical trial of the effectiveness of Eustachian tube inflation and atomization in the treatment of secretory otitis media (ChiCTR) - P=N/A | N=354 | Recruiting | Sponsor: Shandong Second People's Hospital; Shandong Second People's Hospital

New trial • Otorhinolaryngology

BiRCh: A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) (clinicaltrials.gov) - P2 | N=288 | Active, not recruiting | Sponsor: Insmed Incorporated | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study (clinicaltrials.gov) - P2 | N=64 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study (clinicaltrials.gov) - P2 | N=64 | Not yet recruiting | Sponsor: Sanofi

New P2 trial • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Treatment of allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Stapokibart (CM310) in patients with uncontrolled seasonal allergic rhinitis (PHECDA): Rationale and design of a multicentre, randomized, double-blind, placebo-controlled study. (PubMed, Asia Pac Allergy) - P3 | "In addition to SoC, which includes mometasone furoate nasal spray and loratadine, participants are randomly assigned using a centralized interactive-web-response-system to receive either subcutaneous Stapokibart 600 (loading dose)-300 mg or a placebo every 2 weeks for 4 weeks. The PHECDA study is for the first time to provide insight into the efficacy and safety of a seasonal add-on Stapokibart for patients with uncontrolled SAR during pollen exposure. NCT05908032."

Clinical • Journal • Allergic Rhinitis • Immunology • Inflammation • IL4R

A Randomized Comparison of Bencycloquidium Bromide, Mometasone Furoate, and a Combination for Persistent Allergic Rhinitis. (PubMed, J Allergy Clin Immunol Pract) - P4 | "Bencycloquidium bromide was superior to MFNS in reducing daily runny nose symptoms. The combination of BCQB and MFNS was superior to MFNS alone in alleviating TNSS in patients with moderate to severe persistent AR with a predominant symptom of runny nose."

Clinical • Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • CCL11 • IL6

Safety and onset time of modified Yupingfeng nasal spray versus mometasone furoate nasal spray on house dust mites-induced moderate to severe allergic rhinitis: a prospective, multicenter, randomized, open-label, parallel-group clinical trial. (PubMed, J Ethnopharmacol) - "Both MYN and MFN effectively reduce AR symptoms; however, MFN acts more quickly than MYN in relieving these symptoms, while MYN is associated with fewer side effects. The therapeutic effects of MYN may be linked to the regulation of the PTEN/NF-κB/TSLP signaling pathway."

Journal • Allergic Rhinitis • Immunology • Inflammation • IL10 • IL6 • PTEN • TNFA • TSLP

CEREN1: A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (clinicaltrials.gov) - P3 | N=210 | Recruiting | Sponsor: Sanofi

New P3 trial • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

CEREN2: A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (clinicaltrials.gov) - P3 | N=210 | Recruiting | Sponsor: Sanofi

New P3 trial • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Deep needling at Xiaguan (ST7) combined with electroacupuncture and warm acupuncture for adenoid hypertrophy in children: a randomized controlled trial (PubMed, Zhongguo Zhen Jiu) - "Deep needling at Xiaguan (ST7) combined with electroacupuncture and warm acupuncture could effectively improve symptoms, reduce adenoid volume, and improve the quality of life in children with AH."

Clinical • Journal • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder